Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Rheumatol Int ; 41(6): 1125-1131, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33844038

ABSTRACT

INTRODUCTION/OBJECTIVE: Xerostomia is one of the main symptoms of primary Sjögren's syndrome (pSS). The unstimulated salivary flow (UWS) test is one of the objective Sjögren's syndrome classification criteria used to assess xerostomia's severity. The study's objective was to evaluate UWS rate measurements (with a threshold rate of 0.1 mL/min) in the screening of patients suspected with pSS, presenting with xerostomia in whom labial salivary gland biopsy (LSGB) should be performed. We will try to answer whether it is possible not to perform LSGB in targeted patients according to UWS results? We analyze the correlation between UWS value and focus score (FS) and anti-SSA antibodies. METHODS: The study group consisted of subjects above 18 years of age with a subjective feeling of oral dryness. RESULTS: A total of 105 subjects were qualified for the study. The final diagnosis of pSS was made in 44 patients according to the classification criteria from 2016. No age differences were identified between pSS patients and control group subjects (patients with dry mouth without autoimmune background). UWS rates were significantly lower in pSS patients than in the control group. No association was identified between UWS and focus score (FS) ≥ 1 in LSGB. No differences were observed between anti-SSA-positive and anti-SSA-negative patients in terms of age, UWS rates, FS. CONCLUSION: LSGB should be performed in all suspected pSS cases regardless of the UWS rate value, particularly in subjects without specific anti-SSA antibodies. In patients with suspected pSS, only less than one-half of the UWS measurements are below the value of 0.1 mL/min adopted as the threshold in the classification criteria for pSS.


Subject(s)
Saliva/metabolism , Salivary Glands/pathology , Sjogren's Syndrome/diagnosis , Adult , Aged , Biopsy/methods , Case-Control Studies , Female , Humans , Male , Middle Aged , Xerostomia/etiology
2.
Adv Clin Exp Med ; 25(3): 479-84, 2016.
Article in English | MEDLINE | ID: mdl-27629736

ABSTRACT

BACKGROUND: The therapeutic effects of cyclophosphamide (CP) in the treatment of systemic rheumatic diseases are related to its immune suppressive activity. However effective, the application of CP is restricted due to multiple adverse effects. OBJECTIVES: This retrospective study was conducted to determine the frequency of adverse effects attributed to CP toxicity. MATERIAL AND METHODS: The study involved 65 patients (17 male; 48 female) receiving intravenous CP between October 2007 and December 2010. The mean age at onset was 51.2 years (range 19-77 years). The most common diagnoses were systemic sclerosis (20), systemic lupus erythematosus (13) and vasculitis (13). The indications for treatment with CP were interstitial lung disease in the course of systemic diseases (33), vasculitis (24), glomerulonephritis (5) and changes in the central nervous system (3). The patients were administered 400-1000 mg CP in intravenous infusions at 2-16 week intervals, with the addition of sodium 2-sulfanylethanesulfonate (mesna) before and after each pulse. RESULTS: Out of 65 patients 40 (60%) reported adverse effects: infections in 24 (37%), nausea in 19 (29%), vomiting in 11 (17%), abdominal pain in 7 (11%) and pancytopenia in one, leading to cessation of the therapy. No association was found between the frequency of side effects and the treatment duration (p = 0.632), age (p = 0.852), diagnosis (p = 0.171) or nominal dose (p = 0.321). CONCLUSIONS: As knowledge about CP continues to increase, this medication remains a safe way to treat many rheumatic diseases.


Subject(s)
Cyclophosphamide/adverse effects , Drug-Related Side Effects and Adverse Reactions/etiology , Rheumatic Diseases/drug therapy , Abdominal Pain/chemically induced , Adult , Aged , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Chi-Square Distribution , Cyclophosphamide/administration & dosage , Drug Administration Schedule , Female , Humans , Infections/chemically induced , Infusions, Intravenous , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Nausea/chemically induced , Retrospective Studies , Rheumatic Diseases/diagnosis , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/drug therapy , Vasculitis/diagnosis , Vasculitis/drug therapy , Vomiting/chemically induced , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...